Results of a systematic literature search published online in Clinical Lymphoma, Myeloma & Leukemia
showed that ibrutinib (Imbruvica) was associated with superior survival and fewer adverse events (AEs) compared with bendamustine (Treanda) in patients with chronic lymphocytic leukemia (CLL).
She added that researchers only observed 37 such AEs among 135 patients in the ibrutinib group. The researchers concluded that, based on this analysis, ibrutinib was a safer option than bendamustine overall, but noted that there were 6 incidents of severe bleeding in the ibrutinib group. There were no such incidents with bendamustine.
Andrasiak I, Rybka J, Knopinska-Posluszny W, Wrobel T. Efficacy and safety of bendamustine and ibrutinib in previously untreated patients with chronic lymphocytic leukemia–indirect comparison [published online March 7, 2017]. Clin Lymphoma Myeloma Leuk. doi: 10.1016/j.clml.2017.02.026.
... to read the full story